• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups.

作者信息

Bacher Ulrike, Haferlach Claudia, Alpermann Tamara, Schnittger Susanne, Kern Wolfgang, Haferlach Torsten

出版信息

Leuk Lymphoma. 2013 Mar;54(3):639-42. doi: 10.3109/10428194.2012.717275. Epub 2012 Aug 21.

DOI:10.3109/10428194.2012.717275
PMID:22853779
Abstract
摘要

相似文献

1
Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups.与治疗相关的骨髓增生异常综合征和急性髓系白血病患者具有共同的遗传特征，但可根据原始细胞计数和细胞遗传学风险谱分为具有预后相关性的亚组。
Leuk Lymphoma. 2013 Mar;54(3):639-42. doi: 10.3109/10428194.2012.717275. Epub 2012 Aug 21.
2
Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.骨髓原始细胞比例在10%至30%之间的骨髓增生异常综合征（MDS）或急性髓系白血病（AML）患者的预后与原始细胞计数无关，而是取决于细胞遗传学和分子遗传学特征。
Leukemia. 2011 Aug;25(8):1361-4. doi: 10.1038/leu.2011.80. Epub 2011 Apr 15.
3
The spectrum of molecular aberrations in myelodysplastic syndromes: in the shadow of acute myeloid leukemia.
Haematologica. 2007 Jun;92(6):723-7. doi: 10.3324/haematol.11471.
4
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.2351 例骨髓增生异常综合征患者的合并多中心分析表明，国际预后评分系统低估了骨髓增生异常综合征不良核型的风险。
J Clin Oncol. 2011 May 20;29(15):1963-70. doi: 10.1200/JCO.2010.28.3978. Epub 2011 Apr 25.
5
[WHO classification of acute myeloid leukaemia (AML) and the myelodysplastic syndrome (MDS)].[世界卫生组织急性髓系白血病（AML）和骨髓增生异常综合征（MDS）分类]
Dtsch Med Wochenschr. 2002 Mar 1;127(9):447-50. doi: 10.1055/s-2002-20422.
6
Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.治疗相关骨髓增生异常综合征和急性髓系白血病中p53频繁过表达：一项骨髓活检的免疫组织化学研究
Mod Pathol. 1993 Sep;6(5):521-5.
7
Searching for clarity in therapy-related myelodysplastic syndrome/acute myeloid leukemia prognostication.探寻治疗相关的骨髓增生异常综合征/急性髓系白血病预后的明晰性。
Leuk Lymphoma. 2013 Mar;54(3):447-8. doi: 10.3109/10428194.2012.728289. Epub 2012 Sep 28.
8
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.细胞遗传学对异基因移植后初发及治疗相关急性髓系白血病和骨髓增生异常综合征预后的影响。
Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64. doi: 10.1016/j.bbmt.2007.01.079. Epub 2007 Mar 21.
9
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.外周血原始细胞百分比高于骨髓：骨髓增生异常综合征、急性淋巴细胞白血病和急性髓细胞白血病的临床意义
Leukemia. 2005 Sep;19(9):1567-72. doi: 10.1038/sj.leu.2403876.
10
Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.原发性骨髓增生异常综合征和急性髓系白血病复杂核型的分子细胞遗传学分析
Cancer Genet Cytogenet. 2006 Feb;165(1):51-63. doi: 10.1016/j.cancergencyto.2005.09.007.

引用本文的文献

1
Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Acute Leukemia.异基因造血干细胞移植治疗相关性急性白血病
Indian J Hematol Blood Transfus. 2021 Oct;37(4):521-527. doi: 10.1007/s12288-020-01334-4. Epub 2020 Aug 12.
2
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.治疗相关性骨髓增生异常综合征需要进行特定的诊断亚分类和风险分层——一种用于 t-MDS 患者分类的方法。
Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020 Jun 29.
3
The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution.
治疗相关髓系肿瘤的突变负担与原发性骨髓增生异常综合征相似，但分布特征不同。
Leukemia. 2019 Dec;33(12):2842-2853. doi: 10.1038/s41375-019-0479-8. Epub 2019 May 14.
4
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.通过下一代测序技术对治疗相关骨髓增生异常综合征和急性髓系白血病进行突变分析，并与初发性疾病进行比较。
Leuk Res. 2015 Mar;39(3):348-54. doi: 10.1016/j.leukres.2014.12.006. Epub 2014 Dec 20.
5
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.治疗相关髓系肿瘤中高 p53 蛋白表达与不良核型和预后不良相关。
Mod Pathol. 2015 Apr;28(4):552-63. doi: 10.1038/modpathol.2014.153. Epub 2014 Nov 21.
6
A focused review of hematopoietic neoplasms occurring in the therapy-related setting.对治疗相关环境中发生的造血系统肿瘤的重点综述。
Int J Clin Exp Pathol. 2014 Jun 15;7(7):3512-23. eCollection 2014.
7
Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.国际预后评分系统修订版在治疗相关骨髓增生异常综合征和少原始细胞急性髓系白血病中的应用
Leukemia. 2014 Jan;28(1):185-9. doi: 10.1038/leu.2013.191. Epub 2013 Jun 21.